578 related articles for article (PubMed ID: 30446166)
21. Castration-resistance prostate cancer: what is in the pipeline?
DE Nunzio C; Presicce F; Giacinti S; Bassanelli M; Tubaro A
Minerva Urol Nefrol; 2018 Feb; 70(1):22-41. PubMed ID: 28707844
[TBL] [Abstract][Full Text] [Related]
22. Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data.
Flaig TW; Potluri RC; Ng Y; Todd MB; Mehra M
Cancer Med; 2016 Feb; 5(2):182-91. PubMed ID: 26710718
[TBL] [Abstract][Full Text] [Related]
23. Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence.
Norum J; Nieder C
Pharmacoeconomics; 2017 Dec; 35(12):1223-1236. PubMed ID: 28756597
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer.
Galletti G; Leach BI; Lam L; Tagawa ST
Cancer Treat Rev; 2017 Jun; 57():16-27. PubMed ID: 28527407
[TBL] [Abstract][Full Text] [Related]
25. [Metastatic castration-resistant prostate cancer : Clinical data, new treatment options and therapy monitoring].
Miller K; Albers P; Eichenauer R; Geiges G; Grimm MO; König F; Mickisch G; Pfister D; Schwentner C; Suttmann H; Zastrow S
Urologe A; 2016 Sep; 55(9):1206-12. PubMed ID: 27411995
[TBL] [Abstract][Full Text] [Related]
26. Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy.
Drake CG; Sharma P; Gerritsen W
Oncogene; 2014 Oct; 33(43):5053-64. PubMed ID: 24276248
[TBL] [Abstract][Full Text] [Related]
27. [Castration resistant prostate cancer 2015].
Merseburger AS; Böker A; Kuczyk MA; von Klot CA
Aktuelle Urol; 2015 Jan; 46(1):59-65. PubMed ID: 25658232
[TBL] [Abstract][Full Text] [Related]
28. Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics.
Mukherji D; Omlin A; Pezaro C; Shamseddine A; de Bono J
Cancer Metastasis Rev; 2014 Sep; 33(2-3):555-66. PubMed ID: 24452758
[TBL] [Abstract][Full Text] [Related]
29. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
[TBL] [Abstract][Full Text] [Related]
30. Therapy Update for Metastatic Castration-Resistant Prostate Cancer.
Dinh JA; Baker D; Chahal M
Consult Pharm; 2016; 31(10):581-592. PubMed ID: 27725068
[TBL] [Abstract][Full Text] [Related]
31. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
[TBL] [Abstract][Full Text] [Related]
32. Treatment options in castration-resistant prostate cancer: current therapies and emerging docetaxel-based regimens.
Saad F; Miller K
Urol Oncol; 2014 Feb; 32(2):70-9. PubMed ID: 23506965
[TBL] [Abstract][Full Text] [Related]
33. New drugs in the treatment of elderly patients with metastatic castration-resistance prostate cancer.
Genestreti G; Di Battista M; Cavallo G; Brandes AA
Tumori; 2016 Aug; 102(4):361-6. PubMed ID: 27151879
[TBL] [Abstract][Full Text] [Related]
34. Advances in systemic therapies for metastatic castration-resistant prostate cancer.
Pant MK; Abughaban A; Aragon-Ching JB
Future Oncol; 2014 Nov; 10(14):2213-26. PubMed ID: 25471035
[TBL] [Abstract][Full Text] [Related]
35. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
[TBL] [Abstract][Full Text] [Related]
36. Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.
Cereda V; Formica V; Massimiani G; Tosetto L; Roselli M
Expert Opin Investig Drugs; 2014 Apr; 23(4):469-87. PubMed ID: 24490883
[TBL] [Abstract][Full Text] [Related]
37. Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary.
O'Sullivan JM; Abramowitz E; Sierra-Scacalossi L
Future Oncol; 2023 May; 19(15):1021-1028. PubMed ID: 36942803
[TBL] [Abstract][Full Text] [Related]
38. Novel agents for castration-resistant prostate cancer: Early experience and beyond.
Fujimoto N
Int J Urol; 2016 Feb; 23(2):114-21. PubMed ID: 26311471
[TBL] [Abstract][Full Text] [Related]
39. Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view.
Bracarda S; Sisani M; Marrocolo F; Hamzaj A; Del Buono S; Altavilla A
Expert Rev Anticancer Ther; 2014 Nov; 14(11):1283-94. PubMed ID: 25353258
[TBL] [Abstract][Full Text] [Related]
40. Molecular alterations and emerging targets in castration resistant prostate cancer.
Lorente D; De Bono JS
Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]